Parabacteroides goldsteinii mitigates parkinsonism in LRRK2 mutant mice by reducing neuroinflammation through

Jian-Da Lin1, Hsun Li2, Chia-Lang Hsu3

  • 1Department of Biochemical Science and Technology, National Taiwan University, Taipei, Taiwan.

PubMed
Abstract

Insights

Administering Parabacteroides goldsteinii before motor symptoms emerge can slow Parkinson's disease (PD) progression. This gut bacterium restores intestinal balance and reduces neuroinflammation, offering therapeutic potential for early-stage PD.

Area of Science:

  • Neuroscience
  • Microbiology
  • Immunology

Background:

  • Parkinson's disease (PD) is linked to gut microbiota alterations and inflammation.
  • LRRK2 gene mutations are a significant genetic risk factor for PD and inflammatory bowel disease.
  • Parabacteroides goldsteinii shows potential in reducing intestinal and systemic inflammation.

Purpose of the Study:

  • To investigate the therapeutic effect of P. goldsteinii colonization on PD progression before motor dysfunction onset.
  • To assess the impact of P. goldsteinii on LRRK2-associated parkinsonism in a pre-symptomatic stage.

Main Methods:

  • Established a germ-free LRRK2 G2019S-mutant PD mouse model.
  • Administered P. goldsteinii orally at the pre-symptomatic stage.
  • Utilized transcriptomic, cytokine profiling, RNA sequencing, flow cytometry, and bioenergetic analyses to assess central and intestinal changes.

Main Results:

  • P. goldsteinii colonization improved motor performance and reduced neuropathology, including α-synuclein aggregation and dopaminergic neurodegeneration.
  • Neuroprotection involved IL-12 receptor signaling, suppressed microglial activation, and reduced LRRK2 kinase activity.
  • Intestinal effects included suppressed TLR4 inflammation, expanded CD4+CD8αα+ T cells, improved epithelial barrier function, and enhanced mitochondrial bioenergetics.

Conclusions:

  • P. goldsteinii attenuates LRRK2-associated parkinsonism by restoring gut homeostasis and reducing neuroinflammation.
  • Modulating the gut-immune-brain axis via P. goldsteinii shows therapeutic promise for prodromal PD.
  • Targeting the gut microbiota may offer a novel strategy for early PD intervention.